How to define transarterial chemoembolization failure or refractoriness: a European perspective.

摘要: In Europe, trans-arterial chemoembolization (TACE) is usually given to patients with Barcelona Clinic Liver Cancer (BCLC) "intermediate stage" hepatocellular carcinoma (HCC), and associated a modest improvement in median overall survival. the two positive randomized trials that have been reported, TACE was stopped cases of severe toxicity, worsening liver cirrhosis or performance status tumor progression, including local extrahepatic spread portal vein thrombosis. The necessity stop leads concept untreatable which characterized by massive involvement, spread, vascular invasion, impaired function status. More recently, assessment for re-treatment (ART) score has developed determine will not benefit from second third therapy. Herein, we propose an algorithm summarizes our experience TACE.